VINBLASTINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C46H58N4O9
Molecular Weight	810.9741
Optical Activity	UNSPECIFIED
Defined Stereocenters	9 / 9
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12N3CC[C@@]14C5=CC(=C(OC)C=C5N(C)[C@@]4([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]6(C[C@@]7([H])CN(C[C@](O)(CC)C7)CCC8=C6NC9=C8C=CC=C9)C(=O)OC

InChI

InChIKey=JXLYSJRDGCGARV-CFWMRBGOSA-N

InChI=1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37-,38+,39+,42-,43+,44+,45-,46-/m0/s1

HIDE SMILES / InChI

Description
Sources: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue_Bedford%20Labs/55390-091-10%20VIN%2010MG/5539009110
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24404355

Vinblastine is a Vinca alkaloid obtained from the Madagascar periwinkle plant. Vinca alkaloids were found out in the 1950's by Canadian scientists, Robert Noble and Charles Beer for the first time. Medicinal applications of this plant lead to the monitoring of these compounds for their hypoglycemic activity, which is of little importance compared to their cytotoxic effects. They have been used to treat diabetes, high blood pressure and the drugs have even been used as disinfectants. Nevertheless, the vinca alkaloids are so important for being cancer fighters. The mechanism of action of vinblastine sulfate has been related to the inhibition of microtubule formation in the mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. Vinblastine is an antineoplastic agent used to treat Hodgkin's disease, non-Hodgkin's lymphomas, mycosis fungoides, cancer of the testis, Kaposi's sarcoma, Letterer-Siwe disease, as well as other cancers.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Tubulin 69 Target ID: CHEMBL2095182 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1260766 \| https://www.ncbi.nlm.nih.gov/pubmed/8534917 \| http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue_Bedford%20Labs/55390-091-10%20VIN%2010MG/5539009110	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Hodgkin's lymphoma 34 Sources: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue_Bedford%20Labs/55390-091-10%20VIN%2010MG/5539009110	Primary	Approved 8429	VINBLASTINE SULFATE Approved Use Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) Histiocytic lymphoma Mycosis fungoides (advanced stages) Advanced carcinoma of the testis Kaposi’s sarcoma Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies Choriocarcinoma resistant to other chemotherapeutic agents Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active., Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active. Launch Date 1987
Non-Hodgkin's lymphoma 79 Sources: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue_Bedford%20Labs/55390-091-10%20VIN%2010MG/5539009110	Primary	Approved 8429	VINBLASTINE SULFATE Approved Use Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) Histiocytic lymphoma Mycosis fungoides (advanced stages) Advanced carcinoma of the testis Kaposi’s sarcoma Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies Choriocarcinoma resistant to other chemotherapeutic agents Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active., Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active. Launch Date 1987
Mycosis fungoides 30 Sources: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue_Bedford%20Labs/55390-091-10%20VIN%2010MG/5539009110	Primary	Approved 8429	VINBLASTINE SULFATE Approved Use Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) Histiocytic lymphoma Mycosis fungoides (advanced stages) Advanced carcinoma of the testis Kaposi’s sarcoma Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies Choriocarcinoma resistant to other chemotherapeutic agents Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active., Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active. Launch Date 1987
Carcinoma of the testis 2 Sources: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue_Bedford%20Labs/55390-091-10%20VIN%2010MG/5539009110	Primary	Approved 8429	VINBLASTINE SULFATE Approved Use Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) Histiocytic lymphoma Mycosis fungoides (advanced stages) Advanced carcinoma of the testis Kaposi’s sarcoma Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies Choriocarcinoma resistant to other chemotherapeutic agents Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active., Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active. Launch Date 1987
Kaposi’s sarcoma 13 Sources: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue_Bedford%20Labs/55390-091-10%20VIN%2010MG/5539009110	Primary	Approved 8429	VINBLASTINE SULFATE Approved Use Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) Histiocytic lymphoma Mycosis fungoides (advanced stages) Advanced carcinoma of the testis Kaposi’s sarcoma Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies Choriocarcinoma resistant to other chemotherapeutic agents Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active., Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active. Launch Date 1987
Letterer-Siwe disease (histiocytosis X) 2 Sources: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue_Bedford%20Labs/55390-091-10%20VIN%2010MG/5539009110	Primary	Approved 8429	VINBLASTINE SULFATE Approved Use Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) Histiocytic lymphoma Mycosis fungoides (advanced stages) Advanced carcinoma of the testis Kaposi’s sarcoma Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies Choriocarcinoma resistant to other chemotherapeutic agents Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active., Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active. Launch Date 1987

T_1/2

Value	Dose	Analyte	Population
26.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7070351/	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	VINBLASTINE serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
16.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7070351/	14 mg single, intravenous dose: 14 mg route of administration: Intravenous experiment type: SINGLE co-administered:	VINBLASTINE serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
31.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7070351/	7 mg single, intravenous dose: 7 mg route of administration: Intravenous experiment type: SINGLE co-administered:	VINBLASTINE serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
1173 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/889590/	0.2 mg/kg single, intravenous dose: 0.2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	VINBLASTINE serum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
0.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6873152/			VINBLASTINE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6873152/			VINBLASTINE serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1.3 mg/m2 1 times / day multiple, intravenous MTD Dose: 1.3 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1.3 mg/m2, 1 times / day Co-administed with:: valspodar, i.v(10 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4727	unhealthy, 18-73 n = 6 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 18-73 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4727	DLT: Neutropenia, Ileus... Dose limiting toxicities: Neutropenia (grade 4, 16.7%) Ileus (grade 4, 16.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4727
2.6 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 2.6 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 2.6 mg/m2, 1 times / day Co-administed with:: valspodar, i.v(5 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726	unhealthy, 18-73 n = 3 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 18-73 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726	DLT: Neutropenia, Ileus... Dose limiting toxicities: Neutropenia (grade 4, 33.3%) Ileus (grade 4, 33.3%) Neutropenic fever (grade 4, 33.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726
2.6 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 2.6 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 2.6 mg/m2, 1 times / day Co-administed with:: valspodar, i.v(4 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726	unhealthy, 18-73 n = 4 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 18-73 Sex: M+F Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726	DLT: Neutropenia, Fatigue... Dose limiting toxicities: Neutropenia (grade 4, 50%) Fatigue (grade 3, 25%) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726
10 mg/m2 1 times / month multiple, intravenous MTD Dose: 10 mg/m2, 1 times / month Route: intravenous Route: multiple Dose: 10 mg/m2, 1 times / month Co-administed with:: cyclosporine, p.o(17 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/7747714 Page: p.254	unhealthy, 31-70 n = 3 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 31-70 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/7747714 Page: p.254	DLT: Neutropenia, Sepsis... Dose limiting toxicities: Neutropenia (grade 4, 66.7%) Sepsis (grade 5, 16.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/7747714 Page: p.254

AEs

AE	Significance	Dose	Population
Ileus	grade 4, 16.7% DLT	1.3 mg/m2 1 times / day multiple, intravenous MTD Dose: 1.3 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1.3 mg/m2, 1 times / day Co-administed with:: valspodar, i.v(10 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4727	unhealthy, 18-73 n = 6 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 18-73 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4727
Neutropenia	grade 4, 16.7% DLT	1.3 mg/m2 1 times / day multiple, intravenous MTD Dose: 1.3 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1.3 mg/m2, 1 times / day Co-administed with:: valspodar, i.v(10 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4727	unhealthy, 18-73 n = 6 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 18-73 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4727
Ileus	grade 4, 33.3% DLT	2.6 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 2.6 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 2.6 mg/m2, 1 times / day Co-administed with:: valspodar, i.v(5 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726	unhealthy, 18-73 n = 3 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 18-73 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726
Neutropenia	grade 4, 33.3% DLT	2.6 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 2.6 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 2.6 mg/m2, 1 times / day Co-administed with:: valspodar, i.v(5 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726	unhealthy, 18-73 n = 3 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 18-73 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726
Neutropenic fever	grade 4, 33.3% DLT	2.6 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 2.6 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 2.6 mg/m2, 1 times / day Co-administed with:: valspodar, i.v(5 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726	unhealthy, 18-73 n = 3 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 18-73 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726
Fatigue	grade 3, 25% DLT	2.6 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 2.6 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 2.6 mg/m2, 1 times / day Co-administed with:: valspodar, i.v(4 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726	unhealthy, 18-73 n = 4 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 18-73 Sex: M+F Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726
Neutropenia	grade 4, 50% DLT	2.6 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 2.6 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 2.6 mg/m2, 1 times / day Co-administed with:: valspodar, i.v(4 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726	unhealthy, 18-73 n = 4 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 18-73 Sex: M+F Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726
Neutropenia	grade 4, 66.7% DLT	10 mg/m2 1 times / month multiple, intravenous MTD Dose: 10 mg/m2, 1 times / month Route: intravenous Route: multiple Dose: 10 mg/m2, 1 times / month Co-administed with:: cyclosporine, p.o(17 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/7747714 Page: p.254	unhealthy, 31-70 n = 3 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 31-70 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/7747714 Page: p.254
Sepsis	grade 5, 16.7% DLT, Disc. AE	10 mg/m2 1 times / month multiple, intravenous MTD Dose: 10 mg/m2, 1 times / month Route: intravenous Route: multiple Dose: 10 mg/m2, 1 times / month Co-administed with:: cyclosporine, p.o(17 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/7747714 Page: p.254	unhealthy, 31-70 n = 3 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 31-70 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/7747714 Page: p.254

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587 inducer 781	inhibitor 1767	inhibitor 1852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2C8 911 CYP2C19 1478 CYP2E1 882 MDR3 8 MRP1 106 MRP2 383 MRP3 157 MRP4 204 BSEP 402 BCRP 699 OATP1B1 788 OATP1B3 706 OATP2B1 123 OCT1 512	CYP3A 191 P-gp 1537 MDR3 3 MRP1 107 MRP2 205	P-gp 257 MRP1 48 MRP2 111 BCRP 75

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1692	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1OSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2A6 739	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1OSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C19 1553	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1OSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C9 1819	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1OSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2E1 970	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1OSJ9fQ%3D%3D	no [IC50 >10 uM]
MRP3 207	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
BCRP 773	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/19421845/	no
MDR3 9	inhibitor 3277 Sources: https://transportal.compbio.ucsf.edu/compounds/vinblastine/	no
OATP2B1 126	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/	no
OCT1 543	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/18788725/	no
CYP2C8 965	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/26721703/	weak [IC50 100 uM]
MRP2 475	inhibitor 3277 Sources: https://go.drugbank.com/drugs/DB00570 \| https://go.drugbank.com/articles/A15931 \| https://pubmed.ncbi.nlm.nih.gov/19421845/ \| https://pubmed.ncbi.nlm.nih.gov/23956101/	yes [IC50 21 uM]
MRP1 172	inhibitor 3277 Sources: https://go.drugbank.com/drugs/DB00570 \|https://pubmed.ncbi.nlm.nih.gov/8621644/ \| https://pubmed.ncbi.nlm.nih.gov/18457386/	yes [IC50 30 uM]
CYP3A4 1925	inhibitor 3277 Sources: https://go.drugbank.com/drugs/DB00570 \| https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTU5In19	yes [IC50 32 uM]
MRP4 238	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	yes [IC50 35.1 uM]
OATP1B3 715	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/ \| https://pubmed.ncbi.nlm.nih.gov/25618019/	yes [IC50 43.5 uM]
OATP1B1 803	inhibitor 3277 Sources: https://go.drugbank.com/drugs/DB00570 \|https://pubmed.ncbi.nlm.nih.gov/21861202/ \| https://pubmed.ncbi.nlm.nih.gov/25618019/ \| https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNjk3NjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1OSJ9fQ%3D%3D	yes [IC50 46.8 uM]
BSEP 403	inhibitor 3277 Sources: https://go.drugbank.com/drugs/DB00570 \|https://go.drugbank.com/articles/A16121 \| https://pubmed.ncbi.nlm.nih.gov/23956101/	yes [IC50 62 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://go.drugbank.com/drugs/DB00570 \| https://pubmed.ncbi.nlm.nih.gov/8258200/	yes [Ki 42 uM]
BCRP 773	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/31155684/	yes
MRP1 172	inducer 1573 Sources: https://go.drugbank.com/drugs/DB00570 \| https://pubmed.ncbi.nlm.nih.gov/12429346/	yes
MRP2 475	inducer 1573 Sources: https://go.drugbank.com/drugs/DB00570 \| https://pubmed.ncbi.nlm.nih.gov/15849751/	yes
P-gp 1650	inducer 1573 Sources: https://go.drugbank.com/drugs/DB00570 \| https://pubmed.ncbi.nlm.nih.gov/12429346/	yes
CYP3A4 1925	inducer 1573 Sources: https://go.drugbank.com/drugs/DB00570 \| https://pubmed.ncbi.nlm.nih.gov/20959500/	yes	yes (co-administration study) Comment: Vinblastine increased the median (95% CI) clearance of the CYP3A4 phenotyping probe midazolam from 21.7 L/h (12.6 to 28.1) to 32.3 L/h (17.3 to 53.9) (p = 0.0156, Wilcoxon signed-rank test). Sources: https://go.drugbank.com/drugs/DB00570 \| https://pubmed.ncbi.nlm.nih.gov/20959500/

Drug as victim

Target	Modality	Activity	Clinical evidence
MRP2 205	substrate 3367 Sources: https://go.drugbank.com/drugs/DB00570 \| https://transportal.compbio.ucsf.edu/compounds/vinblastine/	yes [Km 137.3 uM]
P-gp 1537	substrate 3367 Sources: https://go.drugbank.com/drugs/DB00570 \| https://go.drugbank.com/articles/A15815 \| https://transportal.compbio.ucsf.edu/compounds/vinblastine/	yes [Km 89.2 uM]
CYP3A4 1737	substrate 3367 Sources: https://go.drugbank.com/drugs/DB00570 \| https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.04d&code=C930&ns=ncit&type=relationship&key=932053897&b=1&n=0&vse=null	yes
MDR3 3	substrate 3367 Sources: https://transportal.compbio.ucsf.edu/compounds/vinblastine/ \| https://pubmed.ncbi.nlm.nih.gov/20190787/	yes
MRP1 107	substrate 3367 Sources: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.12889	yes
CYP3A 191	substrate 3367 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77&type=display	yes	yes (co-administration study) Comment: Enhanced toxicity has been reported in patients receiving concomitant erythromycin Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77&type=display

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA019FUD	https://www.aablocks.com/goods/Goods/detail?id=AA019FUD
AHH Chemical co.,ltd	NP-0159	http://www.ahhchemical.com/product/NP-0159.html
AK Scientific, Inc. (AKSCI)	Q943	http://www.aksci.com/item_detail.php?cat=Q943
Aaron Chemicals	AR019GM5	http://www.aaronchem.com/865-21-4
AbMole Bioscience	M4347	http://www.abmole.com/products/vinblastine.html
Achemtek	0102-014586	http://www.achemtek.com/865-21-4
Acorn PharmaTech	ACN-047385	http://www.acornpharmatech.com/
Alsachim	1117	http://www.alsachim.com/product-C3219-glo.bal-view.html
Ambinter	Amb22801678	http://www.ambinter.com/reference/22801678
ApexBio Technology	N2256	http://www.apexbt.com/vinblastine.html
Aurora Fine Chemicals LLC	A24.076.208	http://online.aurorafinechemicals.com/info?ID=A24.076.208
Aurora Fine Chemicals LLC	K16.667.094	http://online.aurorafinechemicals.com/info?ID=K16.667.094
Aurum Pharmatech LLC	W-5281	http://www.Aurumpharmatech.com/Product/ProductDetails/W_5281
AvaChem Scientific	1012B	http://www.avachem.com/productSearch.asp?1012B
BOC Sciences	865-21-4	https://www.bocsci.com/vinblastine-cas-865-21-4-item-84-78578.html
BOC Sciences	15228-71-4	https://www.bocsci.com/vinrosidine-cas-15228-71-4-item-59529.html
BioCrick	BCN2376	http://www.biocrick.com/Vinblastine-BCN2376.html
BioSynth	Q-100868	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-100868.html
Calbiochem	677175	http://www.emdbiosciences.com/product/677175
Chem Scene	CS-1336	http://www.chemscene.com/865-21-4.html
ChemFaces	CFN90230	http://www.chemfaces.com/natural/Vinblastine-CFN90230.html
ChemMol	30107940	http://www.chemmol.com/chemmol/30107940.html
ChemMol	49428962	http://www.chemmol.com/chemmol/49428962.html
ChemMol	99158126	http://www.chemmol.com/chemmol/99158126.html
Chemspace	CSSB00159262891	https://chem-space.com/CSSB00159262891
Chemspace	CSSB02125592927	https://chem-space.com/CSSB02125592927
Chemspace	CSSB02235353200	https://chem-space.com/CSSB02235353200
Clearsynth	CS-P-01207	https://www.clearsynth.com/en/CSP01207.html
DC Chemicals	DCC-002	http://www.dcchemicals.com//product_show-Vinblastine.html
Debye Scientific	DB-050310	http://www.debyesci.com/cas_865-21-4.html
EMD Millipore	677175	http://www.emdbiosciences.com/product/677175
Glentham Life Sciences	GP2901	http://www.glentham.com/products/product/GP2901/
Hairui	HR122895	http://www.hairuichem.com/en/product/865-21-4.html
Herbest Bio-Tech	HH231713	http://www.bjherbest.com/analytical-standard/alkaloids/vinblastine-865-21-4.html
Lab Network	LN01343210	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01343210
Lab Network	LN03258097	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN03258097
MedChem Express	HY-17418	https://www.medchemexpress.com/Vinblastine.html
MolPort	MolPort-005-910-359	https://www.molport.com/shop/molecule-link/MolPort-005-910-359
MuseChem	I005196	https://www.musechem.com/product/I005196.html
OChem	12831	http://www.ocheminc.com/index.php?act=psearch&pid=865V214
Parchem	30287	http://www.parchem.com/chemical-supplier-distributor/Vinblastine-020287.aspx
Selleck Chemicals	S1248	http://www.selleckchem.com/products/Vinblastine.html
Smolecule	S568857	https://www.smolecule.com/products/s568857
Smolecule	S599355	https://www.smolecule.com/products/s599355
Smolecule	S616017	https://www.smolecule.com/products/s616017
Synchem UG and Co KG	67402	http://www.synchem.de/chemical_Vinblastine.html
THE BioTek	bt-302979	https://www.thebiotek.com/product/others/bt-302979
THE BioTek	bt-318822	https://www.thebiotek.com/product/others/bt-318822
THE BioTek	bt-333873	https://www.thebiotek.com/product/others/bt-333873
THE BioTek	bt-338291	https://www.thebiotek.com/product/others/bt-338291
THE BioTek	bt-345135	https://www.thebiotek.com/product/others/bt-345135
Vitas-M Laboratory	STL453006	http://www.request.vitasmlab.com/index.php?option=com_search_stk&Itemid=22&stk=STL453006&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink
Yuhao Chemical	XJ1373	http://www.chemyuhao.com/865-21-4.html
iChemical	EBD2185099	http://www.ichemical.com/products/865-21-4.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule	MCULE-7852064208	https://mcule.com/MCULE-7852064208/
mcule	MCULE-9967454324	https://mcule.com/MCULE-9967454324/

PubMed

Title	Date	PubMed
[Clinical evaluation of the efficacy of modern first, second, and third line regimes of chemotherapy in patients with disseminated cutaneous melanoma].	2001	11710284
Chemotherapy versus best supportive care in stage IV non-small cell lung cancer, non metastatic to the brain.	2001 Mar-Apr	11460205
[Neoadjuvant chemotherapy and conservative surgery in invasive bladder cancer. Personal experience].	2001 Sep	11723435
5-fluorouracil-Induced cardiotoxicity.	2002 Jan-Feb	11999096
The role of combined method in organ-sparing treatment of muscle-invasive bladder cancer recurrences.	2002 Jun	12161935
[Cerebellar, pulmonary and cutaneous localizations of juvenile xanthogranuloma].	2002 Mar	11988687
[Diagnostic difficulties in primary mesothelioma].	2004	15757264
The use of vinca alkaloids in adult patients with refractory chronic idiopathic thrombocytopenia.	2004 Dec	15595999
Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization.	2004 May	15568225
Anticancer agents are potent neurotoxins in vitro and in vivo.	2004 Sep	15349862
Development and characterization of an immobilized human organic cation transporter based liquid chromatographic stationary phase.	2005 Apr 25	15734168
Crystal structure of vinorine synthase, the first representative of the BAHD superfamily.	2005 Apr 8	15665331
Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer.	2005 Feb 14	15685237
Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents.	2005 May 5	15735699
Cytoskeletal architecture differentially controls post-transcriptional processing of IL-6 and IL-8 mRNA in airway epithelial-like cells.	2006 May 15	16499908
A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo.	2006 Nov 15	17107616
[Chemotherapy of advanced non small cell lung cancer: effect on survival and symptoms affecting quality of life].	2007	18080983
Vinflunine in the treatment of bladder cancer.	2008 Dec	19337431
Kaposi's sarcoma of the hand mimicking squamous cell carcinoma in a woman with no evidence of HIV infection: a case report.	2008 Jun 19	18565232
[Metastases from urethelial carcinoma: role of chemotherapy].	2008 Nov	19070803
Anterior segment manifestations of human immunodeficiency virus/acquired immune deficiency syndrome.	2008 Sep-Oct	18711264
Identifying tumor stem-like cells in mouse melanoma cell lines by analyzing the characteristics of side population cells.	2009 Aug	19477285
Initiation of hepatitis C virus infection requires the dynamic microtubule network: role of the viral nucleocapsid protein.	2009 May 15	19269968
Retrospective French nationwide survey of childhood aggressive vascular anomalies of bone, 1988-2009.	2010 Feb 3	20128925
Simple and reproducible HPLC-DAD-ESI-MS/MS analysis of alkaloids in Catharanthus roseus roots.	2010 Jan 5	19720492
Distinct roles for Dectin-1 and TLR4 in the pathogenesis of Aspergillus fumigatus keratitis.	2010 Jul 1	20617171

Patents

Sample Use Guides

In Vivo Use Guide

It is wise to initiate therapy for adults by administering a single intravenous dose of 3.7 mg/m2 of body surface area (bsa). Thereafter, white-blood-cell counts should be made to determine the patient’s sensitivity to vinblastine sulfate. A simplified and conservative incremental approach to dosage at weekly intervals for adults may be outlined as follows: First dose ........................... 3.7 mg/m2 bsa Second dose ........................... 5.5 mg/m2 bsa Third dose ........................... 7.4 mg/m2 bsa Fourth dose ........................... 9.25 mg/m2 bsa Fifth dose ........................... 11.1 mg/m2 bsa The above-mentioned increases may be used until a maximum dose not exceeding 18.5 mg/m2 bsa for adults is reached. The dose should not be increased after that dose which reduces the white-cell count to approximately 3000 cells/mm3 . In some adults, 3.7 mg/m2 bsa may produce this leukopenia; other adults may require more than 11.1 mg/m2 bsa; and, very rarely, as much as 18.5 mg/m2 bsa may be necessary. For most adult patients, however, the weekly dosage will prove to be 5.5 to 7.4 mg/m2 bsa. When the dose of vinblastine sulfate which will produce the above degree of leukopenia has been established, a dose of 1 increment smaller than this should be administered at weekly intervals for maintenance. Thus, the patient is receiving the maximum dose that does not cause leukopenia. It should be emphasized that, even though 7 days have elapsed, the next dose of vinblastine sulfate should not be given until the white-cell count has returned to at least 4000/mm3. In some cases, oncolytic activity may be encountered before leukopenic effect. When this occurs, there is no need to increase the size of the subsequent doses

Route of Administration: Intravenous

In Vitro Use Guide

15 nM vinblastine inhibit CHO cell proliferation

Name

Type

Language

VINBLASTINE

Official Name

English

VINBLASTINE [VANDF]

Common Name

English

vinblastine [INN]

Common Name

English

VINCRISTINE SULFATE IMPURITY H [EP IMPURITY]

Common Name

English

Vinblastine [WHO-DD]

Common Name

English

VINBLASTINA

Brand Name

English

NSC-47842

Code

English

VINBLASTINE [HSDB]

Common Name

English

VINDESINE SULFATE IMPURITY B [EP IMPURITY]

Common Name

English

VINBLASTINE [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C932